Comprehensive Analysis Identifies PI3K/Akt Pathway Alternations as an Immune-Related Prognostic Biomarker in Colon Adenocarcinoma Patients Receiving Immune Checkpoint Inhibitor Treatment

Figure 3

The relationship between PI3K/Akt pathway mutations and enhanced immunogenicity. (a) Comparison of DDR mutations in the PI3K/Akt-MT and PI3K/Akt-WT groups in the immunotherapy cohort. (b) Comparison of TMB in the PI3K/Akt-MT and PI3K/Akt-WT groups in the immunotherapy cohort. (c) Comparison of DDR mutations in the PI3K/Akt-MT and PI3K/Akt-WT groups in the TCGA cohort. (d) Comparison of TMB in the PI3K/Akt-MT and PI3K/Akt-WT groups in the Local-COAD cohort. (e) Comparison of TMB between PI3K/Akt-MT and PI3K/Akt-WT groups in the TCGA cohort. (f) Comparison of NAL between PI3K/Akt-MT and PI3K/Akt-WT groups in the TCGA cohort. (g) Comparison of MANTIS scores of the PI3K/Akt-MT and PI3K/Akt-WT groups in the TCGA cohort (; ; ; ; Mann–Whitney test).

(a)

(b)

(c)

(d)

(e)

(f)

(g)